Eli Lilly's Mounjaro Added to China's National Health Insurance for Type 2 Diabetes

Eli Lilly's drug Mounjaro will be included in China's national health insurance reimbursement list starting January 1 for patients with type 2 diabetes, according to the National Healthcare Security Administration. Inclusion in this list typically expands drug accessibility in China, but price reductions often accompany increased sales volumes. Mounjaro was launched in China in January 2024, following the earlier introduction and reimbursement inclusion of a similar diabetes drug, Novo Nordisk's Ozempic.